http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ILMN
-
Illumina To Webcast Upcoming Investor Conferences
-
Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries
-
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2023
-
Veracyte (VCYT) Announces In Vitro Diagnostic Agreement with Illumina (ILMN) to Broaden Availability of Its Tests for Patients Globally
-
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
-
Illumina launches advanced liquid biopsy assay to enable comprehensive genomic profiling of solid tumors
-
Illumina (ILMN) responds to European Commission's divestiture order
-
Illumina responds to European Commission's divestiture order
-
Illumina Posted a Stewardship-Focused Presentation for Investors
-
Illumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023
-
Illumina (ILMN) Appoints Jacob Thaysen as CEO
-
Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer
-
Illumina To Webcast Upcoming Investor Conference
-
Illumina (ILMN) Announces Solutions Center in India
-
Illumina expands genomics capabilities in India with opening of Solutions Center
-
Illumina To Webcast Upcoming Investor Conference
-
Illumina (ILMN) Appoints Steven Barnard as CTO
-
Dr. Steven Barnard Appointed Chief Technology Officer
-
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2023
-
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
-
Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options
-
Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
-
The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck
-
Illumina (ILMN) Launches DRAGEN 4.2
-
Illumina DRAGEN™ 4.2 delivers most accurate and comprehensive coverage of the genome, powering greater applications and discovery
-
Illumina releases 2022 Corporate Social Responsibility Report
-
Illumina's (ILMN) Board of Directors elects two experienced Independent Directors to Board
-
Illumina's Board of Directors elects two experienced Independent Directors to Board
-
Illumina (ILMN) unveils AI software to predict disease-causing genetic mutations in patients
-
Illumina unveils AI software to predict disease-causing genetic mutations in patients
-
Illumina to Host Third Annual Virtual ESG Investor Event on Monday, June 12, 2023
-
Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing
-
Pluton Biosciences Raises $16.5M Series A led by Illumina Ventures and RA Capital to discover and deploy microbes that will fight climate change
-
Illumina's genomic technologies enable better pathogen preparedness and response
-
Illumina increases equitable access to STEM education, reaching over 1 million learners
-
Illumina Reports Financial Results for First Quarter of Fiscal Year 2023; Announces Commitment to Accelerate Margin Growth
-
Illumina's cloud-based informatics programs recognized for robust, international data privacy protections
-
Illumina (ILMN) and Henry Ford Health Partner to Study Impact of Comprehensive Genomic Testing for Cardiovascular Patients
-
Illumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients
-
Illumina celebrates 25 years of innovation
-
Illumina to Announce First Quarter 2023 Financial Results on Tuesday, April 25, 2023
-
Illumina (ILMN) NovaSeq X exceeds 200th order milestone in first quarter 2023
-
Illumina's revolutionary NovaSeq X exceeds 200th order milestone in first quarter 2023
-
Illumina (ILMN) Will Appeal FTC Decision in Federal Court, Will Seek US Resolution by Late 2023 or Early 2024
-
Illumina Will Appeal FTC Decision in Federal Court, Will Seek US Resolution by Late 2023 or Early 2024
-
DNA Data Storage Alliance Announces Board Appointments
-
Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease
-
Illumina (ILMN) launches its first product enabling long- and short-read sequencing on one instrument
-
Illumina launches its first product enabling long- and short-read sequencing on one instrument

